Insulin resistance is more prevalent in patients with systemic lupus erythematosus than controls, increasing the risk of prediabetes, type 2 diabetes mellitus, and morbidity.
Understanding the mechanisms linking insulin resistance, type 2 diabetes, and systemic lupus erythematosus may allow for better treatment strategies to mitigate cardiovascular and metabolic risks.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by damage to multiple systems and a higher risk of cardiovascular disease. In addition, several studies have found that insulin resistance (IR) is more prevalent in SLE patients than controls, increasing the risk of prediabetes, type 2 diabetes mellitus (T2DM) and morbidity. The objective of this review article was to summarize the most relevant evidence about the relationship among IR, T2DM and SLE, including the effects of proinflammatory states, acute-phase proteins, pro-inflammatory cytokines, and pharmacological SLE treatment. A better understanding of the mechanisms involved in these comorbidities will allow better treatment strategies.
García‐Carrasco et al. (Mon,) conducted a review in Systemic lupus erythematosus. Insulin resistance vs. Controls without insulin resistance was evaluated. Insulin resistance is more prevalent in patients with systemic lupus erythematosus than controls, increasing the risk of prediabetes, type 2 diabetes mellitus, and morbidity.